Celcuity Tech Stack
Clinical-stage oncology biotech developing targeted PI3K/AKT/mTOR inhibitor for solid tumors
Celcuity is a public clinical-stage biotech advancing gedatolisib, a potential first-in-class PAM pathway inhibitor for HR+/HER2- breast cancer and metastatic prostate cancer. The hiring mix—dominated by sales (11 roles) and healthcare (10 roles) with senior/director-level fills—signals an organization scaling toward Phase 3 readiness and commercialization rather than core drug discovery. Tech stack leans on regulatory and trial-management tools (Veeva, Medidata Rave, EudraVigilance, SAS) with active pain points in clinical site identification, trial conduct, and payer alignment, indicating execution friction common to late-stage development.
Tech Stack 14 technologies
What Celcuity Is Building
◆Challenges
- Barriers to access
- Unmet medical education needs
- High-risk compliance issues
- Improving patient access to oncology therapies
- Aligning evidence generation with payer needs
- Identifying clinical trial sites
- Troubleshooting clinical trial issues
- Crm integration challenges
- Us launch and clinical use
- Inefficient territory alignment
▲Active Projects
- Develop business plans for territory execution
- Commercialization of gedatolisib
- Territory execution and pull-through of gedatolisib therapy
- Clinical trial site identification and education
- Clinical trial conduct troubleshooting
- Phase i-iii oncology clinical trials
- Territory account and business plans
- Clinical database design
- Qms orientation for new hires
- Collaborative research partnerships
Hiring Activity
Department
Seniority
Notable leadership hires: Biostatistics Director, Medical Director
